AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 222 min read$MRNA

Moderna (MRNA) and Merck (MRK) Stocks Drop Amid Melanoma Vaccine

Moderna (MRNA) and Merck (MRK) stocks fell 24% and 3.6% respectively due to unverified reports of lower-than-expected efficacy in their melanoma vaccine trial. Moderna's P/S ratio is high at 8.6x, and insiders sold $62M in shares. The company's GF Score is 54/100, indicating mixed financial performance.

Original reporting
gurufocus.com
Published Oct 22, 2026, 5:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 6:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$MRNA
Bearish
high confidence
Mentioned
$MRNA · $MRK
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$MRNABearishHigh
01

Why it matters

The unverified leak triggered immediate sell‑offs, highlighting market sensitivity to trial credibility in biotech.

02

Market read

Both stocks experienced notable intraday declines, indicating short‑term trading opportunities and sector‑wide risk considerations.

03

What to watch

Potential positive impact from other pipeline assets may cushion long‑term valuation.

Relevance 7/10Novelty 7/10Timing: today

Background

The article reports a sudden stock decline for Moderna and Merck after rumors of a melanoma vaccine trial data leak, without official confirmation.

Company-level read

Ticker impact

$MRNABearishHigh confidence
Context

Moderna shares fell 24% after unverified reports of a melanoma vaccine trial leak.

Expected impact

likely continued pressure as the leak remains unverified and could affect upcoming trial milestones

Evidence & confidence

The 24% drop is a direct market reaction to the leak news; no new data offsets the negative sentiment.

$MRKBearishHigh confidence
Context

Merck stock dropped 3.6% following the same leaked melanoma vaccine report.

Expected impact

potential further downside if the leak is confirmed or if trial timelines are delayed

Evidence & confidence

Even a smaller decline signals market sensitivity to the unverified trial information.

Market effects

Sector

Biotech sector may see broader risk aversion toward oncology trial news.

Regional

U.S. markets could see a slight dip in biotech indices.

Global

Limited to investors tracking major vaccine developers.

Counterpoint

What could challenge this read

If the leak proves false, the sharp decline could present a buying opportunity.

Key entities

  • Company
    Moderna Inc.

    US‑listed biotech developing mRNA‑based melanoma vaccine.

  • Company
    Merck & Co.

    US‑listed pharma co‑developer of the melanoma vaccine.

Read at source← All news

StoryMerck and Moderna report positive Phase 3 melanoma vaccine results

Also covered by

5 outlets

Related articles

OCT 22
$MRKHighAI 8/10

RBC Capital reiterates Merck stock rating on melanoma trial data

RBC Capital reiterated a Sector Perform rating and $145 price target for Merck (MRK) after melanoma trial data showed a recurrence-free survival hazard ratio of 0.58. The stock is near its 52-week high, up 76% year-to-date. Analysts expect regulatory filings in the U.S. and Europe, with FDA approval anticipated in 2027. Merck is set to announce earnings on October 29, with mixed analyst expectations.

investing.com2 min
OCT 22
$MRNAHigh

Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall

Merck and Moderna reported that their combined mRNA cancer vaccine and immunotherapy reduced melanoma death or recurrence risk by 42% in a Phase 3 trial. Moderna shares fell 17% despite prior gains, while Merck shares dropped 1.8%. The vaccine, tested with Keytruda, showed significant efficacy, with 82.2% of patients cancer-free after two years. The companies plan to seek US approval and launch in 2027.

devdiscourse.com2 min
OCT 22
$MRNAHighAI 8/10

Why Moderna (MRNA) stock is trading lower today

Moderna (MRNA) stock fell 18.3% to $201.80 after partial Phase 3 data for its cancer vaccine with Merck leaked, showing positive results but causing a sell-off. The trial showed a 42% reduction in recurrence or death risk. Moderna's shares are volatile, up 551% YTD but down 18.2% from its 52-week high.

tradingview.com2 min